Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87

Kawai,Sadayuki; Kato,Shunsuke; Imai,Hiroo; Okada,Yoshinari; Ishioka,Chikashi

doi:10.3892/or.2012.2120

Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87

Authors:
- Sadayuki Kawai
- Shunsuke Kato
- Hiroo Imai
- Yoshinari Okada
- Chikashi Ishioka
View Affiliations

Affiliations: Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai 980-8575, Japan
Published online on: November 1, 2012 https://doi.org/10.3892/or.2012.2120
Pages: 13-20
Copyright: © Kawai et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lewis Y (LeY) antigen is an oligosaccharide that is highly expressed at the cell surface in various human cancers. Increased LeY expression activates epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) and promotes cell proliferation in EGFR-overexpressing cells. However, the effect of downregulation of LeY expression on cell proliferation in HER2-overexpressing cells remains unknown. FUT1 encodes α1,2-fucosyltransferase, a key enzyme for LeY synthesis. We knocked down FUT1 by short interfering RNA (siRNA) in four HER2-overexpressing human cancer cell lines, including NCI-N87, MKN7, SKBr3 and BT474. We investigated whether downregulation of LeY and alteration in the glycosylation status of these cells affect cell proliferation and HER2 activation. Knocking down FUT1 expression markedly inhibited proliferation of NCI-N87, which highly expressed EGFR and was sensitive to EGFR deprivation. Furthermore, FUT1 siRNA downregulated the total amount of HER2 protein, phosphorylation of HER2 and EGFR, and phosphorylation of extracellular signal-regulated kinase (ERK) in this cell line. Moreover, the marked downregulation of phosphorylation of HER2 and ERK was observed following short-time EGF-stimulation. These effects were not observed in the other three cell lines. Our results suggest that knockdown of FUT1 downregulates HER2 signaling via EGFR downregulation. FUT1 may serve as a new molecular target for HER2-overexpressing human cancers with activated EGFR signaling.

View Figures

View References

1	Roseman S: Reflections on glycobiology. J Biol Chem. 276:41527–41542. 2001. View Article : Google Scholar : PubMed/NCBI
2	Liu YC, Yen HY, Chen CY, et al: Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci USA. 108:11332–11337. 2011. View Article : Google Scholar : PubMed/NCBI
3	Javaud C, Dupuy F, Maftah A, et al: The fucosyltransferase gene family: an amazing summary of the underlying mechanisms of gene evolution. Genetica. 118:157–170. 2003. View Article : Google Scholar : PubMed/NCBI
4	Matzhold EM, Helmberg W, Wagner T, et al: Identification of 14 new alleles at the fucosyltransferase 1, 2, and 3 loci in Styrian blood donors, Austria. Transfusion. 49:2097–2108. 2009. View Article : Google Scholar : PubMed/NCBI
5	Dettke M, Pálfi G and Loibner H: Activation-dependent expression of the blood group-related Lewis Y antigen on peripheral blood granulocytes. J Leukoc Biol. 68:511–514. 2000.PubMed/NCBI
6	Hokke CH, Neeleman AP, Koeleman CA and van den Eijinden DH: Identification of an α3-fucosyltransferase and a novel α2-fucosyltransferase activity in cercariae of the schistosome Trichobilharzia ocellata: biosynthesis of the Fucα1-->2Fucα1-->3[Gal(NAc)β1-->4] GlcNAc sequence. Glycobiology. 8:393–406. 1998.
7	Nakagoe T, Fukushima K, Itoyanagi N, et al: Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol. 128:257–264. 2002. View Article : Google Scholar : PubMed/NCBI
8	Tsuboi K, Asao T, Ide M, et al: α1,2-fucosylation is a superior predictor of postoperative prognosis for colorectal cancer compared with blood group A, B, or sialyl Lewis X antigen generated within colorectal tumor tissue. Ann Surg Oncol. 14:1880–1889. 2007.
9	Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I and Durrant LG: High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res. 7:R780–787. 2005. View Article : Google Scholar : PubMed/NCBI
10	Arai Y and Nishida M: Differential diagnosis between normal endometrium and endometrial hyperplasia with immunostaining cytology using anti-LeY monoclonal antibody. Int J Gynecol Cancer. 13:42–46. 2003. View Article : Google Scholar
11	Kim YS, Yuan M, Itzkowitz SH, et al: Expression of LeY and extended LeY blood group-related antigens in human malignant, premalignant, and non-malignant colonic tissues. Cancer Res. 46:5985–5992. 1986.PubMed/NCBI
12	Kitamura K, Stockert E, Garin-Chesa P, et al: Specificity analysis of blood group Lewis-y (Le(y)) antibodies generated against synthetic and natural Le(y) determinants. Proc Natl Acad Sci USA. 91:12957–12961. 1994. View Article : Google Scholar : PubMed/NCBI
13	Iwamori M, Tanaka K, Kubushiro K, et al: Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the α1, 2-fucosyltransferase gene. Cancer Sci. 96:26–30. 2005.PubMed/NCBI
14	Zhao Y, Lin B, Hao YY, et al: The effects of Lewis (y) antigen content on drug resistance to carboplatin in ovarian cancer line RMG-I. Prog Biochem Biophys. 35:1175–1182. 2008.
15	Liu JJ, Lin B, Hao YY, et al: Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol Rep. 23:833–841. 2010.PubMed/NCBI
16	Brennan PJ, Kumogai T, Berezov A, et al: HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene. 19:6093–6101. 2000. View Article : Google Scholar : PubMed/NCBI
17	Slamon DJ, Godolphin W and Jones LA: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
18	Gravalos C and Jimeno A: HER2 in Gastric Cancer: A New Prognostic Factor and a Novel Therapeutic Target. Ann Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
19	Owens MA, Horten BC and Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 5:63–69. 2004. View Article : Google Scholar : PubMed/NCBI
20	Palumberi D, Aldi S, Ermini L, et al: RNA-mediated gene silencing of FUT1 and FUT2 influences expression and activities of bovine and human fucosylated nucleolin and inhibits cell adhesion and proliferation. J Cell Biochem. 111:229–238. 2010.PubMed/NCBI
21	Chang WW, Lee CH, Lee P, et al: Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc Natl Acad Sci USA. 105:11667–11672. 2008. View Article : Google Scholar : PubMed/NCBI
22	Mittendorf EA, Liu Y, Tucker SL, et al: A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 29:3896–3907. 2010. View Article : Google Scholar : PubMed/NCBI
23	Tanner M, Hollmén M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278. 2005. View Article : Google Scholar : PubMed/NCBI
24	Brockhoff G, Heckel B, Schmidt-Bruecken E, et al: Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif. 40:488–507. 2007. View Article : Google Scholar : PubMed/NCBI
25	Patel D, Bassi R, Hooper A, et al: Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Cancer Sci. 99:1611–1617. 2008.PubMed/NCBI
26	Zhang Z, Sun P, Liu J, et al: Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth. Biochim Biophys Acta. 1783:287–296. 2008.
27	Miyoshi E, Moriwaki K and Nakagawa T: Biological function of fucosylation in cancer biology. J Biochem. 143:725–729. 2008. View Article : Google Scholar : PubMed/NCBI
28	Wang X, Gu J, Ihara H, et al: Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem. 281:2572–2577. 2006. View Article : Google Scholar : PubMed/NCBI
29	Dogan I, Cumaoglu A, Aricioglu A and Ekmekci A: Inhibition of ErbB2 by herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line. Mol Cell Biochem. 347:41–51. 2011. View Article : Google Scholar : PubMed/NCBI
30	Bijman MN, van Berkel MP, Kok M, Janmaat ML and Boven E: Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines. Anticancer Drugs. 20:450–460. 2009. View Article : Google Scholar : PubMed/NCBI
31	Kruser TJ and Wheeler DL: Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res. 316:1083–1100. 2010. View Article : Google Scholar : PubMed/NCBI